Skip to content

99% Accuracy: AI Twins Revolutionize ALS Clinical Trials

Unlearn, a company specializing in AI-generated digital twins, has partnered with Trace Neuroscience to enhance ALS research. Unlearn’s Digital Twin Generator (DTG) for ALS, trained on over 13,000 clinical records, predicts individual health progression in clinical trials. Trace Neuroscience will utilize this technology in their Phase 1/2 trial targeting the UNC13A protein, crucial for ALS progression. The collaboration aims to simulate disease progression and inform trial protocols. Unlearn has raised over $130 million in funding, with $50 million secured in its Series C round last year. Additionally, Unlearn integrated data from over 8,000 participants from APST Research into its DTG ALS. The company has also partnered with ProJenX and QurAlis Corporation to advance ALS research using its technology. Other firms like Mesh Bio and Twin Health are also employing digital twin technology for managing chronic diseases.

Source: www.mobihealthnews.com

Related Links

Related Videos